Close

Tralokinumab (TAB-218)

DESCRIPTION CATALOG # SIZE PRICE
Anti-Human IL13 Therapeutic Antibody TAB-218 1mg Please Inquiry

PRODUCT INFORMATION

  • Product Overview
  • Recombinant monoclonal antibody to IL13. Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and inflammatory diseases.
  • Target
  • IL13
  • Type
  • IgG4 - lambda
  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Species Reactivity
  • Human
  • Expression Host
  • CHO
  • Applications
  • Suitable for use in WB, FuncS, IF, Neut, ELISA, FC, IP and most other immunological methods.
  • CAS
  • 1044515-88-9
  • Specificity
  • Tested positive against native human antigen.
  • Protein Construction
  • Immunoglobulin G4, anti-(human interleukin 13) (human monoclonal CAT-354 heavy chain), disulfide with human monoclonal CAT-354 light chain, dimer
  • Predicted N terminal
  • H chain: QVQLVQS; L chain: SYVLTQP
  • Molecular Weight
  • 143870
  • Purity
  • >95.0%. Determined by analysis by RP-HPLC & analysis by SDS-PAGE.
  • Size
  • 1mg
  • Storage
  • At -20°C for one year.

BACKGROUND

  • Antigen Description
  • Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses.
  • Function
  • cytokine activity; interleukin-13 receptor binding; protein binding;
  • Synonyms
  • IL13; interleukin 13; interleukin-13; allergic rhinitis; ALRH; BHR1; Bronchial hyperresponsiveness 1 (bronchial asthma); IL 13; MGC116786; MGC116788; MGC116789; P600; Bronchial hyperresponsiveness-1 (bronchial asthma); IL-13;

Related Products

Online Inquiry

Verification code
Click image to refresh the verification code.

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us